Factor VIII–von Willebrand factor complex (FVIII-VWF complex)

The Factor VIII–von Willebrand factor (FVIII-VWF) complex is a critical non-covalent assembly in blood plasma that is essential for normal hemostasis. Factor VIII serves as a vital cofactor for activated Factor IX in the intrinsic pathway of the coagulation cascade, while von Willebrand factor acts as a large multimeric carrier protein that stabilizes Factor VIII. This stabilization protects Factor VIII from rapid proteolytic degradation and concentrates it at sites of vascular injury (UniProt P00451). Furthermore, von Willebrand factor is responsible for mediating the adhesion of platelets to the damaged vascular subendothelium, a primary step in clot formation (StatPearls, Hemophilia A). Deficiencies or functional defects in Factor VIII result in Hemophilia A, whereas defects in von Willebrand factor lead to von Willebrand disease, the most common inherited bleeding disorder (NIH, National Heart, Lung, and Blood Institute). Therapeutic interventions typically involve the administration of recombinant or plasma-derived FVIII and VWF concentrates to restore clotting function and manage or prevent bleeding episodes (DrugBank).

Other names

Factor VIII/von Willebrand factor complexFVIII-VWFAntihemophilic factor-von Willebrand factor complexCoagulation factor VIII/von Willebrand factor complex

Replacement therapy restores deficient levels of Factor VIII or von Willebrand factor to the blood to facilitate the coagulation cascade and platelet plug formation. von Willebrand factor acts as a chaperone, binding to Factor VIII to protect it from proteolytic degradation by activated protein C and preventing its premature clearance from circulation (UniProt P00451, P04275). Additionally, VWF bridges platelets to the subendothelial matrix at sites of vascular injury (StatPearls, von Willebrand Disease).